drug · antibody
leronlimab
Phase 2updated 5mo agoby $CYDY CytoDyn Inc.🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 7 investigational indications.
indications
indications
NSCLCMelanoma
targets
C-C chemokine receptor type 5
all catalysts(0)
nothing on the calendar yet
Trials studying leronlimab
- phase2CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
- —An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
- phase2Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
- phase2Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
- phase2Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
- —A Compassionate Use Study of Leronlimab in Breast Cancer
- phase2Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
News(1)
- CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaquesCytoDyn's leronlimab may have struggled to secure approval as an HIV treatment, but research in infant primates has offered fresh hope for the CCR5-targeting antibody's ability to treat the virus.fiercebiotech · 1mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that